Esomeprazole With Sildenafil Citrate in Women With Early-onset Preeclampsia

• Status: Recruiting
• Trial end date: 2022-01-01
• Target enrollment: 0
• Participant gender: Female

Summary

Previous studies have shown that expectant management of preeclampsia in the context of extreme prematurity may improve perinatal outcomes. Indeed, it has been estimated that for each additional day of pregnancy prolongation between 24 and 32 weeks of gestation, there is a nonlinear corresponding gain of 1% in fetal survival. In this study, we evaluate the use of Esomeprazole alone or with Sildenafil Citrate for the treatment of singleton pregnancies complicated by preeclampsia. We hypothesized that the potential increase in uteroplacental and fetoplacental blood flow with the use of Esomeprazole alone or with Sildenafil Citrate may be associated with pregnancy prolongation (the primary study outcome) and improved maternal and perinatal outcomes.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aswan University Hospital
• Treatments: Citric Acid; Esomeprazole; Sildenafil Citrate; Sodium Citrate

Criteria

Inclusion Criteria:

• Pregnant women presenting at a Gestational age between 28 + 0 weeks and 32 + 0 weeks presented with preterm preeclampsia

• The patient will be managed with an expectant management

• Give written informed consent

Exclusion Criteria:

• Multiple pregnancies.

• Previous hypersensitivity reaction esomeprazole or sildenafil citrate

• Contraindications to the use of esomeprazole or sildenafil citrate

• The patient is unable or unwilling to give consent

• An established fetal compromise that necessitates delivery